Zhou Jianghua, Sun Dan-Qin, Targher Giovanni, D Byrne Christopher, Lee Byung-Wan, Hamaguchi Masahide, Kim Seung Up, Hou Xuhong, Fadini Gian Paolo, Shimabukuro Michio, Furuhashi Masato, Wang Ning-Jian, Tilg Herbert, Zheng Ming-Hua
Department of Cardiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Department of Nephrology, The Affiliated Wuxi No. 2 People's Hospital of Nanjing Medical University, Affiliated Wuxi Clinical College of Nantong University, Wuxi, Jiangsu, China.
eGastroenterology. 2023 Aug 7;1(1):e100005. doi: 10.1136/egastro-2023-100005. eCollection 2023 Jun.
Metabolic dysfunction-associated fatty liver disease (MAFLD) is an alternative description and classification of non-alcoholic fatty liver disease (NAFLD) that may have better utility than NAFLD in clinical practice. We performed a meta-analysis to quantify the magnitude of the association between MAFLD and risk of both prevalent and incident chronic kidney disease (CKD).
We systematically searched PubMed, Medline (OVID), Embase (OVID), Web of Science and Cochrane Library from database inception until 29 May 2022. We included observational studies examining the association between MAFLD and risk of CKD, defined by estimated glomerular filtration rate ≤60 mL/min/1.73 m or presence of abnormal albuminuria. Meta-analysis was performed using random-effects models to obtain summary HRs or ORs with 95% CIs.
Seventeen observational studies with aggregate data on 845 753 participants were included in meta-analysis. In the 7 cohort studies, the pooled random-effects HR for incident CKD in patients with MAFLD was 1.29 (95% CI 1.17 to 1.41, I=87.0%). In the 10 cross-sectional studies, the pooled random-effects OR for prevalent CKD in patients with MAFLD was 1.35 (95% CI 1.11 to 1.64, I=92.6%).
MAFLD is significantly associated with an increased prevalence and incidence of CKD.
CRD42022352366.
代谢功能障碍相关脂肪性肝病（MAFLD）是非酒精性脂肪性肝病（NAFLD）的另一种描述和分类，在临床实践中可能比NAFLD具有更好的实用性。我们进行了一项荟萃分析，以量化MAFLD与慢性肾脏病（CKD）的患病率和发病率之间关联的强度。
我们系统检索了从数据库建立至2022年5月29日的PubMed、Medline（OVID）、Embase（OVID）、Web of Science和Cochrane图书馆。我们纳入了观察性研究，这些研究考察了MAFLD与CKD风险之间的关联，CKD的定义为估计肾小球滤过率≤60 mL/min/1.73 m²或存在白蛋白尿异常。使用随机效应模型进行荟萃分析，以获得汇总风险比（HRs）或比值比（ORs）及95%置信区间（CIs）。
17项观察性研究纳入荟萃分析，汇总数据涉及845753名参与者。在7项队列研究中，MAFLD患者发生CKD的合并随机效应HR为1.29（95%CI 1.17至1.41，I²=87.0%）。在10项横断面研究中，MAFLD患者CKD患病率的合并随机效应OR为1.35（95%CI 1.11至1.64，I²=92.6%）。
MAFLD与CKD患病率和发病率的增加显著相关。
CRD42022352366。
